Latest Pharma and Biotech News
Biotechnology
28 November 2024 Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma.
Today's issue
Refine Search
Biotechnology
Privately-held US biotech Tetra Therapeutics has presented data showing that TNF-blocking agents reduce the risk of Alzheimer’s disease in patients with rheumatoid arthritis or psoriasis. 5 December 2019
Biotechnology
US biotech firm Axsome Therapeutics yesterday announced that its AXS-12 (reboxetine) met the prespecified primary endpoint and significantly reduced the number of cataplexy attacks as compared to placebo in patients with narcolepsy in the CONCERT Phase II trial. 4 December 2019
Biotechnology
USA-based Puma Biotechnology and privately-held French drugmaker Pierre Fabre have agreed to extend the terms of the license agreement in which Puma granted Pierre Fabre exclusive rights to develop and commercialize Nerlynx (neratinib) within Europe and part of Africa. 4 December 2019
Biotechnology
The US Food and Drug Administration has approved Tecentriq (atezolizumab) in combination with chemotherapy (Abraxane [paclitaxel protein-bound; nab-paclitaxel] and carboplatin) for the initial (first-line) treatment of adults with metastatic non-squamous non-small cell lung cancer (NSCLC) with no EGFR or ALK genomic tumor aberrations. 4 December 2019
Biotechnology
French biotech ImCheck Therapeutics has raised $53 million in a Series B financing to advance its clinical pipeline of gamma delta T-cell-focused antibodies for cancer and autoimmune diseases. 4 December 2019
Biotechnology
Australian plasma and cell and gene therapy specialist CSL Limited is steadily advancing its R&D pipeline and capabilities to deliver a highly differentiated product portfolio mix, addressing a broader range of patients’ unmet needs,” said head of Research & Development Dr William Mezzanotte today. 4 December 2019
Biotechnology
French drugmaker Sanofi is presenting clinical data from its insulin portfolio at the 2019 congress of the International Diabetes Federation, in Busan, South Korea. 4 December 2019
Biotechnology
Privately-held UK biotech Mission Therapeutic and US major AbbVie today announced the identification of several deubiquitylating enzymes (DUBs) as potential drug targets in their Alzheimer’s and Parkinson’s R&D collaboration. 3 December 2019
Biotechnology
India's Biocon, Asia's premier biotechnology company, has named Siddharth Mittal as its new chief executive and joint managing director. 3 December 2019
Biotechnology
Astellas Pharma on Monday evening announced that it has entered into a definitive agreement to acquire US biotech Audentes Therapeutics at a price of $60.00 per share in cash. 3 December 2019
Biotechnology
Texan biopharma Lexicon Pharmaceuticals lost more than 10% of its marke
t value on Monday as the company suffered a new setback in the development of Zynquista (sotagliflozin). 3 December 2019
Biotechnology
French healthcare non-profit Médecins Sans Frontières (MSF) has called on Gavi, the Vaccine Alliance, to stop payments to pharma majors Pfizer and GlaxoSmithKline for their pneumococcal vaccine. 3 December 2019
Biotechnology
Japan’s Astellas Pharma and USA-based Seattle Genetics have entered into a clinical collaboration agreement with pharma giant Merck & Co to evaluate the combination of their antibody-drug conjugate (ADC) enfortumab vedotin and Merck’s anti-PD-1 therapy, Keytruda (pembrolizumab), in patients with previously untreated metastatic urothelial (mostly bladder) cancer. 2 December 2019
Biotechnology
US biotech Neurocrine Biosciences and Canada’s Xenon Pharmaceuticals today announced a license and collaboration agreement to develop first-in-class treatments for epilepsy. 2 December 2019
Biotechnology
Wuxi Biologics’ vaccine arm WuXi Vaccines (WV) expects to become a giant global vaccine supplier with its $240 million investment in the vaccine facility in Ireland last week, said the WuXi Vaccines chairman Chris Chen at a press meeting held on November 29 in Shanghai. 2 December 2019
Biotechnology
Cambridge Innovation Capital (CIC), the UK venture capital investor enabling visionaries to build global, category-leading companies in the Cambridge ecosystem, has provided an update on its performance for the six months ended September 30, 2019, showing it has attracted £1 billion ($1.29 billion) of investments into Cambridge companies. 2 December 2019
Biotechnology
The Australian subsidiary of AbbVie has announced the federal government’s decision to list Skyrizi (risankizumab), a new treatment option for adults living with severe chronic plaque psoriasis, which eligible Australian patients will be able to access from December 1, 2019 on the Pharmaceutical Benefits Scheme (PBS). 2 December 2019
Biotechnology
AstraZeneca and US partner Merck & Co on Friday announced the recommendation of Lynparza (olaparib) by UK health technology assessor the National Institute for Health and Care Excellence (NICE) for maintenance treatment of relapsed, platinum-sensitive ovarian cancer in adults with a BRCA-mutation and who have had two or more courses of platinum-based chemotherapy. 30 November 2019
Biotechnology
The US Food and Drug Administration has accepted a supplemental Biologics License Application (sBLA) and granted Priority Review for Imfinzi (durvalumab) for the treatment of patients with previously untreated extensive-stage small cell lung cancer (SCLC). 29 November 2019
Biotechnology
Positive news results of the SAkuraSky Study, a global Phase III clinical study of satralizumab (development code: SA237) have published in the online version of The New England Journal of Medicine (NEJM). 29 November 2019
All news
Biotechnology
Allink Biotherapeutics, a Chinese start-up focused on bispecific antibody and antibody-drug conjugates (ADC), has raised $42 million in a financing round led by Lanchi Ventures. 29 November 2024
Biotechnology
China’s Innovent Biologics has announced that the updated 2024 National Reimbursement Drug List (NRDL) now includes Sintbilo (tafolecimab) injection, an anti-PCSK9 monoclonal antibody for the first time. The updated NRDL will be officially effective from January 1, 2025. 29 November 2024
Biotechnology
Zug-based Galderma has published positive results from the Phase III OLYMPIA 1 trial in JAMA Dermatology, as the company’s newly-minted shares change hands in record volumes. 29 November 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has launched its toripalimab in the domestic market, sending the firm’s share up 2%. Toripalimab is a New Biological Entity (NBE), the company noted. 29 November 2024
Biotechnology
French pharma major Sanofi has added a new plant in Singapore to make vaccines and other medicines, as the company seeks to bolster preparedness for emergencies, including potential pandemics, according to Bloomberg and other media reports. 29 November 2024
Biotechnology
During the Belgian Economic Mission to Brazil, a historic Memorandum of Understanding (MoU) was signed between the Brazilian Oswaldo Cruz Foundation (Fiocruz) through its Institute of Technology on Immunobiologicals (Bio-Manguinhos), and the Belgian companies Quantoom Biosciences and Univercells. 29 November 2024
Biotechnology
PTC Therapeutics is to sell its rare pediatric disease priority review voucher (PRV) for $150 million. 28 November 2024
Biotechnology
A report from industry analyst DelveInsight highlights progress in the myotonic dystrophy treatment landscape, with more than 20 companies developing over 22 innovative treatments. 28 November 2024
Biotechnology
The UK subsidiary of Dutch drugmaker argenx confirmed today that its investigational therapy, subcutaneous efgartigimod alfa has been granted Promising Innovative Medicine (PIM) designation by the UK Medicines and Healthcare products Regulatory Agency (MHRA) for the treatment of adults with chronic inflammatory demyelinating polyneuropathy (CIDP). 28 November 2024
Biotechnology
Privately-held French drugmaker Servier has announced the inauguration of its first unit dedicated to the production of biological medicines from its R&D pipeline. 28 November 2024
Biotechnology
The US Food and Drug Administration has received new reports of hematologic malignancies, including life-threatening cases of myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), following treatment of early, active cerebral adrenoleukodystrophy (CALD) patients with Skysona (elivaldogene autotemcel). 28 November 2024
Biotechnology
San Diago, USA-based Acadia Pharmaceuticals yesterday announced it has entered into an exclusive worldwide license agreement with Denmark’s Saniona for the development and commercialization of SAN711, a first-in-class, highly selective GABAA-α3 positive allosteric modulator. 28 November 2024
Biotechnology
Kronos Bio, a biotech with a presence on the east and west coasts of the USA, has unveiled a major restructuring plan. 28 November 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Biotechnology
The European medicines regulator has approved a combo therapy starring PD-1 inhibitor Tevimbra (tislelizumab), from cancer firm BeiGene. 27 November 2024
Biotechnology
After trading closed yesterday, Exelixis revealed that the US Food and Drug Administration (FDA) has notified the company that the supplemental New Drug Application (sNDA) for cabozantinib (Cabometyx) for the treatment of adults with previously treated advanced pancreatic neuroendocrine tumors (pNET) and advanced extra-pancreatic NET (epNET) will be discussed at an Oncologic Drugs Advisory Committee (ODAC) meeting in March 2025. 27 November 2024
Biotechnology
Chengdu-based Kelun-Biotech has received marketing authorization in China for sacituzumab tirumotecan (sac-TMT), a Trop2-directed antibody-drug conjugate (ADC). 27 November 2024
Biotechnology
AI-powered protein engineering company Cradle has raised $73 million in a Series B funding. The European firm, which has now raised more than $100 million in total, calls itself the leading platform for AI-powered protein engineering. 27 November 2024
Biotechnology
US clinical stage biotech Alector saw its shares tumble 35% to $2.57 by close of trading yesterday, as it announced disappointing results from the INVOKE-2 Phase II clinical trial evaluating the safety and efficacy of AL002 in slowing disease progression in individuals with early Alzheimer’s disease (AD). 27 November 2024
Biotechnology
PTC Therapeutics has announced that its Phase II trial for utreloxastat, aimed at treating amyotrophic lateral sclerosis (ALS), failed to meet its primary endpoint. 27 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze